Ofloxacin Ophthalmic (Ocuflox)

Ofloxacin ophthalmic, commonly sold under the brand name Ocuflox, is a second-generation fluoroquinolone antibiotic solution used to treat bacterial eye infections in dogs. Originally developed and approved for human use, ofloxacin has become a valuable tool in veterinary ophthalmology due to its excellent broad-spectrum antibacterial activity, good ocular tissue penetration, and favorable safety profile. The medication is effective against a wide range of gram-positive and gram-negative bacteria commonly responsible for ocular infections in canine patients. Its established efficacy and the availability of generic formulations have made ofloxacin a practical choice for treating bacterial eye conditions in veterinary practice.

The mechanism of action of ofloxacin involves inhibition of bacterial DNA gyrase, an essential enzyme required for DNA replication, transcription, and repair in bacterial cells. By blocking this critical enzyme, ofloxacin prevents bacteria from reproducing and leads to cell death, producing bactericidal rather than merely bacteriostatic effects. This mechanism ensures rapid killing of susceptible organisms, leading to quicker resolution of infection compared to some other antibiotic classes. Ofloxacin demonstrates good activity against common ocular pathogens including Staphylococcus aureus, Streptococcus species, Pseudomonas aeruginosa, Haemophilus influenzae, and many Enterobacteriaceae species.

Ofloxacin ophthalmic is available as a sterile 0.3% solution designed specifically for topical application to the eye. The formulation contains benzalkonium chloride as a preservative, which helps maintain sterility in multi-dose containers throughout their use. Each application delivers a precise amount of medication to the ocular surface, where it is absorbed into the conjunctiva and cornea to achieve therapeutic concentrations at the site of infection. The solution is designed for comfort with appropriate pH and osmolality, though some dogs may experience brief stinging upon application. Both brand-name Ocuflox and generic ofloxacin ophthalmic products are available, with generics offering cost savings while providing equivalent therapeutic benefit.

When used as prescribed under veterinary supervision, ofloxacin ophthalmic demonstrates an excellent safety profile in canine patients. The topical route of administration ensures high drug concentrations at the infection site while minimizing systemic absorption and associated risks. As with all antibiotics, appropriate use based on accurate diagnosis is essential, as ofloxacin is not effective against viral or fungal infections. Pet owners should follow dosing instructions precisely and complete the full prescribed course to achieve optimal outcomes and help prevent the development of antibiotic-resistant bacteria. Veterinary guidance throughout treatment ensures the best possible results for canine patients with bacterial eye infections.

The primary indication for ofloxacin ophthalmic in dogs is the treatment of bacterial conjunctivitis, one of the most frequently encountered eye conditions in veterinary practice. Bacterial conjunctivitis presents with characteristic signs including redness and inflammation of the conjunctival membranes, discharge that may range from watery to thick and purulent, swelling of the tissues around the eye, and evident discomfort manifested as squinting, pawing at the eye, or excessive blinking. Ofloxacin's broad-spectrum coverage makes it an excellent empiric choice when bacterial infection is suspected but the specific causative organism has not been identified. The medication effectively targets most common conjunctival pathogens, leading to rapid clinical improvement in the majority of cases.

Bacterial keratitis, an infection involving the cornea itself, represents another important indication for ofloxacin ophthalmic therapy. Corneal infections are particularly concerning because they can progress rapidly to ulceration, stromal melting, and potentially perforation with catastrophic vision loss if not treated promptly and effectively. Ofloxacin achieves good corneal tissue penetration, allowing it to reach therapeutic concentrations within the infected corneal layers. The medication is frequently prescribed for bacterial corneal ulcers, with treatment intensity varying based on ulcer severity. Superficial ulcers may respond to standard three to four times daily dosing, while deep or progressive ulcers often require more intensive treatment with applications every one to two hours initially.

Ofloxacin ophthalmic is also commonly used to treat blepharitis, an infection or inflammation of the eyelids that frequently has a bacterial component. Dogs with blepharitis typically present with crusty accumulations along the eyelid margins, swelling of the lids, discomfort, and sometimes hair loss around the eyes. While blepharitis may have multiple contributing factors including allergies, parasites, or immune-mediated conditions, secondary bacterial colonization is common and benefits from antibiotic therapy. Ofloxacin solution can be applied to the eye and the inner lid margins to address both conjunctival and lid margin infection simultaneously.

Prophylactic use of ofloxacin ophthalmic following ocular surgery or traumatic eye injuries helps prevent bacterial infection during the vulnerable healing period. Surgical procedures involving the eye or periocular structures create conditions favorable for bacterial colonization, making preventive antibiotic therapy an important component of postoperative care. Similarly, dogs that have sustained corneal abrasions, foreign body injuries, or other ocular trauma may receive ofloxacin to prevent opportunistic infection while damaged tissues heal. This prophylactic application helps protect surgical outcomes and reduces the risk of potentially sight-threatening infectious complications.

Veterinarians select ofloxacin based on several factors including infection type and severity, suspected causative organisms, previous antibiotic exposure, cost considerations, and individual patient factors. As a second-generation fluoroquinolone, ofloxacin offers broader gram-negative coverage than many first-line antibiotics while maintaining useful gram-positive activity. Generic ofloxacin ophthalmic preparations are widely available and typically more affordable than newer fluoroquinolones, making it a cost-effective option for many infections. When culture and sensitivity testing is performed, ofloxacin susceptibility can guide therapy selection. For empiric treatment of uncomplicated bacterial conjunctivitis, ofloxacin represents an excellent balance of efficacy, safety, and affordability.

The dosing protocol for ofloxacin ophthalmic in dogs is established by the prescribing veterinarian based on the specific condition being treated, infection severity, and individual patient considerations. As with other ophthalmic medications, dosing is standardized rather than calculated by body weight, since the volume of the canine conjunctival sac and eye remains relatively consistent across different-sized dogs. The typical dose is one to two drops of the 0.3% solution applied to the affected eye at each treatment interval. Dosing frequency varies considerably depending on the clinical situation, from twice daily for mild prophylactic use to hourly applications for severe corneal infections.

For routine bacterial conjunctivitis of mild to moderate severity, ofloxacin ophthalmic is typically prescribed at a frequency of four times daily for the first two days, followed by four times daily for an additional five days, for a total treatment course of seven days. This represents the manufacturer's recommended regimen and provides consistent antibiotic coverage while remaining manageable for most pet owners. Some veterinarians may modify this schedule based on clinical response, reducing frequency if rapid improvement occurs or extending treatment for more persistent infections. Each application consists of one to two drops instilled into the conjunctival sac of the affected eye or eyes.

Bacterial corneal ulcers require more intensive treatment with ofloxacin ophthalmic, particularly in the initial phase when rapid bacterial killing is critical to preserve vision. Veterinarians may prescribe applications every fifteen minutes to one hour around the clock for the first twenty-four to forty-eight hours, followed by gradual frequency reduction as clinical improvement is observed. A typical step-down protocol might progress from hourly to every two hours, then every four hours, and finally to four times daily for maintenance. Complete treatment for corneal ulcers often extends two weeks or longer, with duration determined by ulcer healing response. Pet owners dealing with intensive treatment schedules should discuss practical strategies with their veterinarian.

Proper administration technique is essential for achieving optimal therapeutic outcomes with ofloxacin ophthalmic. Pet owners should wash their hands before handling the medication, then gently restrain the dog and pull down the lower eyelid to create a small pocket or pouch. One to two drops of solution should be instilled into this conjunctival sac, taking care not to touch the dropper tip to the eye, eyelids, or any other surface that could contaminate the medication. The dog should be allowed to blink naturally to distribute the solution across the eye surface. If the dog shakes its head or immediately paws at the eye, some medication may be lost, potentially requiring retreatment. Gentle restraint and positive reinforcement can help make the process easier with repeated applications.

Missed doses should be administered as soon as remembered, unless the next scheduled dose is imminent. Pet owners should never apply double doses to compensate for missed applications, as this provides no therapeutic benefit and may increase local irritation. For medications prescribed at frequent intervals such as hourly, missing occasional doses is less critical than for those given less frequently. However, consistent administration throughout the treatment course produces the best outcomes. Setting alarms or associating medication times with routine daily events can help owners maintain intensive dosing schedules.

Completion of the full prescribed treatment course is essential when using ofloxacin ophthalmic, even if the eye appears to have returned to normal before all medication has been used. Bacterial infections may show clinical improvement while viable organisms persist in reduced numbers. Premature discontinuation allows surviving bacteria to repopulate the infection site and potentially develop antibiotic resistance. Treatment courses for uncomplicated conjunctivitis typically last seven to fourteen days, while corneal ulcers may require longer therapy. Follow-up examination by the veterinarian is often recommended to confirm complete resolution before stopping treatment.

Ofloxacin ophthalmic is generally well-tolerated by canine patients when used according to veterinary instructions, with the majority of dogs completing treatment without significant adverse effects. The topical ophthalmic route of administration limits systemic absorption, meaning side effects are predominantly local and typically mild in nature. However, pet owners should be aware of potential reactions to ensure early recognition and appropriate response. Understanding the difference between expected minor effects and those requiring veterinary attention helps owners provide optimal care during treatment.

The most commonly observed side effects of ofloxacin ophthalmic are transient local reactions occurring at the time of application. Brief stinging, burning, or discomfort immediately after instilling the drops is reported in a significant percentage of human patients and likely occurs in dogs as well, evidenced by momentary squinting, blinking, or head shaking. This sensation typically resolves within one to two minutes and generally diminishes with repeated applications as the eye becomes accustomed to the medication. Mild conjunctival redness may occur or temporarily increase following application, and some dogs develop increased tearing. These minor reactions do not typically warrant discontinuation of therapy.

Less common but more notable side effects include sustained irritation, pronounced redness, increased discharge, or obvious worsening of ocular comfort following application. These symptoms may indicate local hypersensitivity or allergic reaction to ofloxacin or other components of the formulation, including the benzalkonium chloride preservative. Some dogs may develop contact dermatitis affecting the skin around the eye, particularly with prolonged use. If any of these reactions occur, pet owners should contact their veterinarian promptly, as discontinuation and substitution with an alternative antibiotic may be necessary. True allergic reactions to fluoroquinolone antibiotics are relatively uncommon but can occur in sensitized individuals.

Systemic side effects from topically applied ofloxacin ophthalmic are rare given the limited absorption from this route of administration. In humans receiving systemic fluoroquinolones, various adverse effects including tendon problems, peripheral neuropathy, and central nervous system effects have been reported, but these are dose-dependent and very unlikely with topical ophthalmic use. Nevertheless, pet owners should be alert for any unusual symptoms during treatment and report them to the veterinarian. Gastrointestinal upset, behavioral changes, or gait abnormalities developing during treatment are likely unrelated to the eye medication but warrant evaluation.

Prolonged use of ofloxacin ophthalmic, particularly beyond the veterinarian's recommended treatment duration, carries additional risks. Extended antibiotic exposure can disrupt the normal bacterial flora of the eye, potentially allowing overgrowth of resistant organisms or fungal species not susceptible to fluoroquinolones. While fluoroquinolones are not typically associated with significant effects on corneal healing at standard concentrations, any antibiotic theoretically could affect the microenvironment during wound repair. Treatment should not extend beyond the prescribed period without veterinary consultation. If improvement is not occurring as expected, reevaluation rather than extended treatment is appropriate. Any severe irritation, significant swelling, or signs of allergic reaction warrant immediate discontinuation and veterinary contact.

Ofloxacin ophthalmic should not be used in dogs with known hypersensitivity or previous allergic reactions to ofloxacin or other fluoroquinolone antibiotics. Cross-reactivity among fluoroquinolone class members is well-documented, meaning dogs that have reacted to one fluoroquinolone such as ciprofloxacin, enrofloxacin, marbofloxacin, or moxifloxacin may react to ofloxacin as well. Previous reactions may have manifested as severe local irritation, pronounced swelling, skin reactions, or systemic allergic symptoms. Pet owners should always inform their veterinarian of any known drug allergies or adverse reactions before starting new medications. If hypersensitivity history is uncertain, careful monitoring during initial doses may be warranted.

The use of ofloxacin ophthalmic is contraindicated for viral or fungal ocular infections, as this antibacterial medication has no activity against these pathogens. Using antibiotics for non-bacterial conditions is ineffective and may delay appropriate therapy while the infection progresses. Viral conditions affecting the eye, fungal keratitis following corneal trauma with plant material, and parasitic infections all require different therapeutic approaches. Accurate diagnosis through veterinary examination with appropriate testing should precede antibiotic therapy whenever possible. If empiric treatment is initiated before definitive diagnosis, lack of expected improvement should prompt reconsideration of the underlying condition and potential modification of therapy.

Pregnancy and lactation require consideration when prescribing ofloxacin ophthalmic, though concerns are mitigated by the minimal systemic absorption from topical ophthalmic administration. Systemic fluoroquinolone antibiotics have been associated with cartilage abnormalities in developing fetuses in animal studies, leading to cautious use recommendations during pregnancy. While the risk from ophthalmic administration is considered very low, veterinarians may prefer alternative antibiotics with more established safety data during pregnancy when equally effective options exist. Similarly, nursing mothers should use ofloxacin ophthalmic only when benefits clearly outweigh theoretical risks, as small amounts could potentially be transmitted to nursing puppies.

Young growing puppies warrant consideration when ofloxacin ophthalmic is prescribed, though concerns are primarily theoretical given limited systemic absorption from topical use. Systemic fluoroquinolones have been documented to cause cartilage damage in growing animals, particularly affecting joint surfaces and growth plates. These effects have led to general recommendations against systemic fluoroquinolone use in young dogs until skeletal maturity. While topical ophthalmic administration results in far lower systemic exposure than oral or injectable routes, some veterinarians exercise caution when prescribing fluoroquinolone eye drops to very young puppies, especially for extended treatment courses. For puppies with serious bacterial eye infections, the benefits of appropriate antibiotic therapy typically outweigh theoretical risks. Complete disclosure of age and health status ensures informed veterinary decision-making.

When using ofloxacin ophthalmic in dogs, pet owners should inform their veterinarian of all medications, supplements, and eye products their dog currently receives. While topical ophthalmic medications have limited potential for systemic drug interactions due to minimal bloodstream absorption, clinically significant interactions can occur at the local level when multiple eye medications are used simultaneously. Understanding these potential interactions ensures optimal therapeutic outcomes and prevents inadvertent reduction in drug effectiveness.

The most important interactions involving ofloxacin ophthalmic occur when multiple topical eye medications are prescribed together. If a dog is receiving several types of eye drops or ointments, proper spacing between applications is essential to allow adequate absorption of each medication before the next is applied. Eye drops should generally be administered at least five to ten minutes apart to prevent dilution and washout of previously applied medications. Ointment formulations should always be applied last, as they create an oily barrier that impedes absorption of subsequently applied aqueous solutions. When ofloxacin is prescribed alongside anti-inflammatory agents, glaucoma medications, or tear supplements, the veterinarian will provide specific timing instructions.

Systemic drug interactions are largely theoretical with topically applied ofloxacin given the minimal systemic absorption from ophthalmic administration. However, veterinarians should be aware if a dog is receiving systemic fluoroquinolone antibiotics, as cumulative exposure could theoretically increase the risk of class-related adverse effects. Similarly, drugs known to interact with systemic fluoroquinolones, including certain antacids containing aluminum or magnesium, iron supplements, and some other medications, could theoretically affect any ofloxacin that is absorbed systemically. While clinically significant interactions are unlikely with ophthalmic use, complete medication disclosure allows the veterinarian to consider all potential issues.

Monitoring and communication throughout treatment helps identify any unexpected interactions or treatment problems. Pet owners should report if the infection appears to be worsening despite treatment, if new symptoms develop, or if the dog seems to be reacting poorly to the medication. What sometimes appears to be a drug interaction may actually indicate treatment failure due to a resistant organism or an incorrect initial diagnosis. Culture and sensitivity testing can help guide therapy adjustments when initial treatment is not producing expected results. Any new medications or supplements started during the ofloxacin treatment course should be reported to the veterinarian to allow assessment for potential interactions.

General precautions for ofloxacin ophthalmic use begin with ensuring accurate diagnosis before initiating antibiotic treatment. Not all red, irritated, or discharge-producing eyes are caused by bacterial infection, and using antibiotics for non-bacterial conditions delays appropriate treatment while potentially contributing to antimicrobial resistance. Allergic conjunctivitis, dry eye syndrome, foreign body reactions, glaucoma, uveitis, and viral infections may present with signs similar to bacterial infection but require different therapeutic approaches. Veterinary examination with appropriate diagnostic evaluation should precede antibiotic therapy whenever possible. Pet owners should never use leftover antibiotics from previous infections or medications prescribed for other pets.

While ofloxacin ophthalmic does not have breed-specific metabolic concerns like some systemic medications affected by the MDR1 gene mutation, certain breed characteristics may influence treatment considerations. Brachycephalic breeds including Pugs, Boston Terriers, French Bulldogs, English Bulldogs, Shih Tzus, and Pekingese have prominent, exposed eyes predisposed to injury and infection. These breeds may require more aggressive treatment and closer monitoring during therapy. Breeds with excessive facial skin folds may have chronic bacterial colonization contributing to recurrent infections. Breeds prone to dry eye disease may have compromised ocular surface health affecting both infection susceptibility and treatment response.

Environmental and handling precautions help ensure safe and effective use of ofloxacin ophthalmic throughout the treatment course. The medication should be stored according to label directions, typically at room temperature away from light and heat. Pet owners should wash their hands before and after medication administration. The dropper tip should never contact the eye, eyelids, or any other surface to prevent contamination of the sterile solution. Contaminated medication can introduce additional pathogens into the eye, potentially worsening the condition being treated. Multi-dose containers should be dated when opened and discarded after the recommended period or at treatment completion.

Monitoring during treatment is essential for ensuring therapeutic success and detecting problems early. Clinical improvement typically becomes evident within two to three days of starting appropriate antibiotic therapy, though more severe infections may take longer to show obvious progress. Pet owners should observe for decreased discharge, reduced redness, improved comfort, and resolution of squinting or excessive blinking. Conversely, lack of improvement, worsening symptoms, or development of new signs should prompt veterinary reevaluation. Some infections may involve resistant organisms requiring alternative antibiotics, or may not be bacterial at all. Follow-up examinations as recommended by the veterinarian help ensure complete resolution.

Special populations require additional consideration when prescribing ofloxacin ophthalmic. Very young puppies, particularly those still actively growing, may warrant careful evaluation of the risk-benefit ratio due to theoretical concerns about fluoroquinolone effects on developing cartilage, though systemic absorption from ophthalmic use is minimal. Geriatric dogs may have concurrent health conditions or take multiple medications requiring interaction consideration. Immunocompromised patients, including those receiving chemotherapy or long-term immunosuppressive therapy, may be more susceptible to infections and may respond differently to treatment. Dogs with diabetes or other metabolic conditions may have altered healing responses. Complete health history disclosure helps veterinarians make optimal prescribing decisions.

Proper storage of ofloxacin ophthalmic maintains medication potency and sterility throughout the treatment course. The solution should be stored at room temperature, typically between 59 and 77 degrees Fahrenheit, protected from light. The medication should be kept away from excessive heat, freezing temperatures, and direct sunlight, all of which can degrade the active ingredient or alter formulation stability. A medicine cabinet, drawer, or closed container away from windows and heating sources provides appropriate storage conditions. The medication should remain in its original container with the label intact for proper identification and access to important information including expiration date.

Before each use, the solution should be inspected visually for any changes in color, clarity, or the presence of particles. Ofloxacin ophthalmic should be clear and colorless to pale yellow. Cloudiness, discoloration, or visible particles may indicate contamination or degradation requiring disposal of the product. The bottle cap should be replaced tightly after each use to prevent contamination and evaporation. Once opened, multi-dose containers have limited stability and should be discarded after treatment completion or according to manufacturer guidelines, typically within four weeks of opening. Writing the opening date on the bottle helps track this timeline.

Safe handling and proper disposal protect household members, pets, and the environment. Ofloxacin ophthalmic should be stored out of reach of children and pets at all times. Dogs may be attracted to medication containers due to owner scent and could potentially chew through packaging. When treatment is complete or the medication has expired, remaining solution should be disposed of properly rather than poured down drains or discarded in regular household trash where it could contaminate water systems or be accessed by others. Many veterinary clinics and pharmacies accept unused medications for proper disposal, and community drug take-back programs offer another responsible option. Contact local waste management authorities for specific pharmaceutical disposal guidance.

Ofloxacin ophthalmic can be used safely in dogs of all breeds when prescribed appropriately, though certain breed characteristics may influence treatment considerations and monitoring requirements. Unlike systemic medications affected by the MDR1 gene mutation common in herding breeds such as Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related breeds, topical ophthalmic antibiotics are not significantly impacted by this genetic variation. The minimal systemic absorption from proper ophthalmic administration means MDR1 status does not affect drug safety or dosing for ofloxacin eye drops. However, understanding breed-related ocular anatomy and disease predispositions helps optimize treatment outcomes.

Brachycephalic breeds deserve particular attention when treating ocular infections due to their distinctive facial anatomy. Breeds including Pugs, Boston Terriers, French Bulldogs, English Bulldogs, Shih Tzus, Pekingese, Lhasa Apsos, and Cavalier King Charles Spaniels have prominent, forward-facing eyes with shallow orbits. Many also have incomplete eyelid closure during blinking or sleep, a condition known as lagophthalmos. These anatomical features predispose brachycephalic dogs to corneal exposure, desiccation, trauma, and secondary bacterial infections at higher rates than other breeds. Treatment may need to be more intensive in these patients, healing may be slower due to ongoing exposure issues, and concurrent use of lubricating products may be beneficial. Facial folds common in many brachycephalic breeds can also harbor bacteria contributing to chronic or recurrent ocular infections.

Size considerations affect practical aspects of administering ofloxacin ophthalmic, though they do not change the dosing itself. Very small toy breeds such as Chihuahuas, Yorkshire Terriers, and Maltese have proportionally smaller eyes and may retain slightly less medication in the conjunctival sac, though this typically does not significantly affect therapeutic outcomes. Giant breed dogs including Great Danes, Saint Bernards, Mastiffs, and Irish Wolfhounds may have conformational issues such as entropion or ectropion that predispose them to eye infections and may complicate both treatment and long-term management. Working and hunting dogs that spend significant time outdoors face increased exposure to environmental irritants, foreign bodies, and potential pathogens, affecting both infection risk and the importance of treatment compliance.

Age-related factors intersect with breed considerations in determining optimal treatment approaches. Puppies of any breed have developing immune systems that may affect infection susceptibility and response to treatment. Very young puppies, particularly of breeds that mature slowly, may warrant extra consideration due to theoretical concerns about fluoroquinolone effects on developing cartilage, though systemic absorption from ophthalmic use is minimal. Senior dogs, typically defined as over seven years for large breeds and over ten years for smaller breeds, may have age-related changes affecting tear production, corneal health, and immune function. Breeds known for developing dry eye syndrome at any age, including Cocker Spaniels, English Bulldogs, and West Highland White Terriers, may require concurrent tear supplementation alongside antibiotic therapy. Veterinary guidance ensures appropriate treatment for patients with breed or age-related special considerations.

Several other fluoroquinolone ophthalmic antibiotics serve as alternatives to ofloxacin for treating bacterial eye infections in dogs. Ciprofloxacin ophthalmic, available as Ciloxan, is another second-generation fluoroquinolone with similar gram-negative coverage though somewhat less gram-positive activity. Moxifloxacin ophthalmic, sold as Vigamox, is a fourth-generation fluoroquinolone with enhanced gram-positive activity and excellent overall spectrum. Gatifloxacin and besifloxacin represent additional newer fluoroquinolone options. The choice among these alternatives typically depends on the suspected organism, local resistance patterns, previous treatment history, cost considerations, and individual patient factors. Newer fluoroquinolones may be reserved for resistant infections or cases where first-line agents have failed.

Ophthalmic antibiotics from other pharmacological classes provide alternatives when fluoroquinolones are contraindicated or when different antimicrobial coverage is needed. Aminoglycoside antibiotics including gentamicin and tobramycin offer excellent gram-negative coverage, particularly against Pseudomonas aeruginosa. Erythromycin ophthalmic ointment provides good gram-positive coverage in a soothing ointment base. Chloramphenicol ophthalmic offers very broad coverage including some anaerobic organisms. Triple antibiotic combinations containing neomycin, polymyxin B, and bacitracin provide coverage of both gram-positive and gram-negative organisms in single products. Terramycin ophthalmic ointment offers another broad-spectrum option. Selection depends on the suspected pathogen, infection severity, patient factors, and local prescribing patterns.

Complementary therapies frequently accompany antibiotic treatment for comprehensive management of ocular infections in dogs. Artificial tear supplements help maintain ocular surface health and are particularly important for breeds prone to dry eye or during recovery from corneal ulcers. Anti-inflammatory medications, both steroidal and nonsteroidal, may be prescribed when significant inflammation accompanies bacterial infection, though corticosteroids are strictly contraindicated in the presence of corneal ulceration. Atropine or other cycloplegic agents reduce painful ciliary muscle spasm in cases of deep ulceration or anterior uveitis. Pet owners should never substitute one medication for another or add over-the-counter products without veterinary guidance, as inappropriate combinations may interfere with healing or worsen the underlying condition. All treatment modifications should be discussed with the prescribing veterinarian.